Key Takeaways
- Base Genomics, an epigenetics company focusing on developing blood tests for early-stage cancer and minimal residual disease, is set to revolutionise early cancer detection in the UK.
- The company uses TAPS (TET-assisted pyridine borane sequencing), a novel technology that avoids DNA degradation and cuts sequencing costs.
- By preserving sequence complexity, simultaneous epigenetic and genetic analysis becomes possible, differentiating Base Genomics in the biotech industry.
- The industry can expect significant advancements in early cancer detection, leading to improved survival rates and treatment plans.
TAPS, or TET-assisted pyridine borane sequencing, is an innovative approach that sequences DNA methylation. Developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford, this technology offers unprecedented potential for early cancer detection and could change the biotech industry’s landscape.
Due to the preservation of sequence complexity, TAPS enables simultaneous epigenetic and genetic analysis, broadening the possibilities for cancer research and developing targeted treatment strategies. This differentiation not because it is novel but also because it addresses significant challenges posed by existing methodologies.
Apart from its innovative approach, Base Genomics is also contributing to the life science industry innovation ecosystem. The future of this industry is expected to benefit from the advancements offered by this promising startup. To find out more, you can visit their website, follow them on Twitter, like their Facebook page or check out their profile on Linkedin.
Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.
